Jornal de Pesquisa do Cérebro

TMS for Chemotherapy-related Cognitive Impairment

Abstract

Carol Chen

Cancer is a formidable adversary that affects millions of people worldwide. Over the years, advancements in cancer treatment have improved survival rates, offering hope to many. However, chemotherapy, one of the most common treatment modalities, comes with its own set of challenges. Chemotherapy-related cognitive impairment, often referred to as "chemo brain," is a well-documented and distressing side effect that can significantly impact a patient's quality of life. In recent years, Transcranial Magnetic Stimulation (TMS) has emerged as a promising tool to mitigate the cognitive deficits associated with chemotherapy. This article explores the role of TMS in addressing chemotherapy-related cognitive impairment, its mechanisms, current research findings and potential implications. Chemotherapy-related cognitive impairment is a multifaceted condition characterized by cognitive deficits such as memory problems, difficulty concentrating and reduced executive function. Patients often report feeling mentally "foggy" or as if their cognitive abilities have declined. While it can occur at any stage of cancer treatment, cognitive changes are most prominent during and shortly after chemotherapy. Chemotherapy-induced oxidative stress can damage brain cells and impact cognitive performance. Some chemotherapy regimens can lead to hormonal imbalances, which may influence cognitive function. The emotional distress associated with a cancer diagnosis and treatment can contribute to cognitive impairments.